Press Releases

Asklepion Pharmaceuticals, LLC announces receipt of Orphan Drug Designation from U.S. FDA

Asklepion Pharmaceuticals, LLC announces receipt of Orphan Drug Designation from the U.S. FDA for the prevention of clinical sequelae of acute lung injury induced by cardiopulmonary bypass in pediatric patients. On January 9, 2017, Asklepion Pharmaceuticals, LLC announced that the U.S. Food and Drug Administration (FDA) has

Read more

News Release: March 17, 2015 FDA approves Cholbam to treat rare bile acid synthesis disorders

March 17, 2015, FDA approves Cholbam to treat rare bile acid synthesis disorders.

Read more